MindMed to Host Conference Call and Webcast to Discuss Third Quarter 2024 Financial Results and Provide Business Update
MindMed (NASDAQ: MNMD), a clinical-stage biopharmaceutical company focused on brain health disorders, has scheduled a conference call and webcast for Thursday, November 7, 2024, at 4:30 p.m. ET. The event will cover the company's third quarter 2024 financial results and provide a corporate update. The webcast will be accessible through a registration link, with a replay available on the company's investor relations website for at least 30 days. Participants are encouraged to join 15 minutes before the start time.
MindMed (NASDAQ: MNMD), un'azienda biofarmaceutica in fase clinica focalizzata sulle malattie cerebrali, ha programmato una conferenza telefonica e un webcast per giovedì 7 novembre 2024, alle 16:30 ET. L'evento tratterà i risultati finanziari del terzo trimestre 2024 dell'azienda e fornirà un aggiornamento aziendale. Il webcast sarà accessibile tramite un link di registrazione, e una registrazione sarà disponibile sul sito web delle relazioni con gli investitori dell'azienda per almeno 30 giorni. Si consiglia ai partecipanti di collegarsi 15 minuti prima dell'orario di inizio.
MindMed (NASDAQ: MNMD), una empresa biofarmacéutica en etapa clínica centrada en trastornos de la salud cerebral, ha programado una conferencia telefónica y un webcast para el jueves 7 de noviembre de 2024, a las 4:30 p.m. ET. El evento cubrirá los resultados financieros del tercer trimestre de 2024 de la empresa y proporcionará una actualización corporativa. El webcast será accesible a través de un enlace de registro, y una repetición estará disponible en el sitio web de relaciones con inversores de la empresa durante al menos 30 días. Se anima a los participantes a unirse 15 minutos antes de la hora de inicio.
MindMed (NASDAQ: MNMD), 뇌 건강 장애에 초점을 맞춘 임상 단계의 바이오 제약 회사는 2024년 11월 7일 목요일 오후 4시 30분 ET에 전화 회의 및 웹캐스트를 계획했습니다. 이 행사는 회사의 2024년 3분기 재무 결과를 다루고 기업 업데이트를 제공합니다. 웹캐스트는 등록 링크를 통해 접근할 수 있으며, 회사의 투자자 관계 웹사이트에서 최소 30일 동안 재생이 가능할 것입니다. 참가자들은 시작 15분 전에 참여할 것을 권장합니다.
MindMed (NASDAQ: MNMD), une entreprise biopharmaceutique en phase clinique spécialisée dans les troubles de la santé cérébrale, a programmé une conférence téléphonique et un webcast pour jeudi 7 novembre 2024 à 16h30 ET. L'événement portera sur les résultats financiers du troisième trimestre 2024 de l'entreprise et fournira une mise à jour corporative. Le webcast sera accessible via un lien d'inscription, avec une rediffusion disponible sur le site web des relations avec les investisseurs de l'entreprise pendant au moins 30 jours. Les participants sont encouragés à se joindre 15 minutes avant l'heure de début.
MindMed (NASDAQ: MNMD), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf Erkrankungen der Gehirngesundheit konzentriert, hat eine Telefonkonferenz und einen Webcast für Donnerstag, den 7. November 2024, um 16:30 Uhr ET angesetzt. Die Veranstaltung wird die finanziellen Ergebnisse des dritten Quartals 2024 des Unternehmens behandeln und ein Unternehmensupdate bereitstellen. Der Webcast wird über einen Registrierungslink zugänglich sein, mit einer Wiederholung, die auf der Website der Investor Relations des Unternehmens für mindestens 30 Tage verfügbar ist. Die Teilnehmer werden ermutigt, 15 Minuten vor Beginn beizutreten.
- None.
- None.
Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the Investor Relations section of the MindMed website, ir.mindmed.co, and archived for at least 30 days after the webcast. Those who plan on participating are advised to join 15 minutes prior to the start time.
About MindMed
MindMed is a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health disorders. MindMed trades on NASDAQ under the symbol MNMD.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241024456529/en/
For Media: media@mindmed.co
For Investors: ir@mindmed.co
Source: Mind Medicine Inc.
FAQ
When will MindMed (MNMD) report Q3 2024 earnings?
How can I access MindMed's (MNMD) Q3 2024 earnings call?
Will there be a replay available for MindMed's (MNMD) Q3 2024 earnings call?
